日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Preclinical development of ozuriftamab vedotin (BA3021), a novel ROR2-specific conditionally active biologic antibody-drug conjugate.

ozuriftamab vedotin (BA3021) 是一种新型 ROR2 特异性条件活性生物抗体药物偶联物,其临床前开发

Chang Hwai Wen, Frey Gerhard, Wang Jing, Liu Haizhen, Xing Charles, Chen Jian, Boyle William J, Short Jay M

Preclinical development of mecbotamab vedotin (BA3011), a novel, AXL-specific conditional active biologic antibody-drug conjugate.

mecbotamab vedotin (BA3011) 是一种新型的 AXL 特异性条件活性生物抗体药物偶联物,其临床前开发

Chang Hwai Wen, Wang Jing, Liu Haizhen, Xing Charles, Chen Jian, Frey Gerhard, Boyle William J, Short Jay M

A novel conditional active biologic anti-EpCAM x anti-CD3 bispecific antibody with synergistic tumor selectivity for cancer immunotherapy

一种新型条件性活性生物制剂抗EpCAM x 抗CD3双特异性抗体,具有协同肿瘤选择性,可用于癌症免疫治疗。

Frey, Gerhard; Cugnetti, Ana Paula G; Liu, Haizhen; Xing, Charles; Wheeler, Christina; Chang, Hwai Wen; Boyle, William J; Short, Jay M

Generating tumor-selective conditionally active biologic anti-CTLA4 antibodies via protein-associated chemical switches

通过蛋白质相关化学开关生成肿瘤选择性条件活性生物制剂抗CTLA4抗体

Chang, Hwai Wen; Frey, Gerhard; Liu, Haizhen; Xing, Charles; Steinman, Lawrence; Boyle, William J; Short, Jay M

Neutralization of Clostridium difficile toxin A using antibody combinations

利用抗体组合中和艰难梭菌毒素A

Demarest, Stephen J; Hariharan, Mangala; Elia, Marikka; Salbato, Jared; Jin, Ping; Bird, Colin; Short, Jay M; Kimmel, Bruce E; Dudley, Michael; Woodnutt, Gary; Hansen, Geneviève

Unusual microbial xylanases from insect guts

昆虫肠道中不寻常的微生物木聚糖酶

Brennan, YaLi; Callen, Walter N; Christoffersen, Leif; Dupree, Paul; Goubet, Florence; Healey, Shaun; Hernández, Myrian; Keller, Martin; Li, Ke; Palackal, Nisha; Sittenfeld, Ana; Tamayo, Giselle; Wells, Steve; Hazlewood, Geoffrey P; Mathur, Eric J; Short, Jay M; Robertson, Dan E; Steer, Brian A